UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

Contents

Previous | Next

Publications

Publications from the ILD group that have resulted from the ILD programs participation in clinical trials or use of the UCSF ILD clinical database and biorepository: These publications are the product of the referral of patients to our center by members of the UCSF Interstitial Lung Disease Consortium and the patients with ILD who, through their generosity and efforts, allowed us to conduct clinical research studies in an effort to improve the lives of patients with ILD.

2015

1. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. DePianto DJ, Chandriani S, Abbas AR, Jia G, N’Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ, and Arron JR. Thorax 2015, 70: 48-56.
Read more »

2. Lung Transplantation for Hypersensitivity Pneumonitis. Kern RM, Singer JP, Koth L, Mooney J, Golden J, Hays S, Greenland J, Wolters P, Ghio E, Jones KD, Leard L, Kukreja J, and Blanc PD. Chest 2015, 47: 1558-65.
Read more »

3. Overexpression of Inhibitor of DNA-Binding 2 Attenuates Pulmonary Fibrosis through Regulation of c-Abl and Twist. Yang J, Velikoff M, Agarwal M, Disayabutr S, Wolters PJ, and Kim KK. Am J Path 2015, 185: 1001-1011.
Read more »

4. Transforming growth factor-β and Interleukin-1β signaling pathways converge on the chemokine CCL20 promoter. Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, Wolters P, Lou J, Marks JD, Baron JL, and Nishimura SL. J Biol Chem 2015, 290: 14717-14728.
Read more »

5. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE Jr, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. Respir Med 2015, 109: 1058-62.
Read more »

6. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Eur Respir J. 2015, 45: 1374-81.
Read more »

7. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): Diagnostic and Adjudication Processes. de Andrade J, Schwarz M, Collard HR, Gentry-Bumpass T, Colby T, Lynch D, Kaner R; IPFnet Investigators. Chest. 2015, 148: 1034-42.
Read more »

8. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr. Respir Med. 2015, 109: 914-22.
Read more »

9. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ; IPFnet investigators. Lancet Respir Med. 2015, 3: 388-96.
Read more »

10. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. Chest 2015, 148: 196-201.
Read more »

11. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Su R, Li MM, Bhakta NR, Solberg OD, Darnell EP, Ramstein J, Garudadri S, Ho M, Woodruff PG, Koth LL. Eur Respir J. 2014, 44: 985-93.
Read more »

12. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Assayag D, Kim EJ, Elicker BM, Golden JA, Jones KD, King, TE Jr. Koth LL, Shum AK, Wolters PJ, Collard HR, and Lee JS. Respir Med 2015, 109: 1326-31.
Read more »

13. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Kim SY, Diggans J, Pankratz D, Huang J, Pagan M, Sindy N, Tom E, Anderson J, Choi Y, Lynch DA, Steele MP, Flaherty KR, Brown KK, Farah H, Bukstein MJ, Pardo A, Selman M, Wolters PJ, Nathan SD, Colby TV, Myers JL, Katzenstein AL, Raghu G, Kennedy GC. Lancet Respir Med. 2015, 3: 473-82.
Read more »

14. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis Across Pre-specified Subgroups in INPULSIS®. Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A. Am J Respir Crit Care Med. 2015, (in press).
Read more »

15. Interferon-γ-producing Th17.1 Cells are Increased in Sarcoidosis and More Prevalent Than Th1 Cells. Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, Woodruff PG, Bhakta NR, Christian L, Nguyen CP, Antalek BJ, Benn BS, Hendriks RW, van den Blink B, Kool M, Koth LL. Am J Respir Crit Care Med. 2015, (in press).
Read more »

16. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr. Eur Resp J 2015, (in press).
Read more »

2014

1. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Lubin M, Chen H, Elicker B, Jones KD, Collard HR, Lee JS. Chest 2014, 145: 1333-8.

2. Subacute onset of Pulmonary Langerhans’ - Cell Histiocytosis With Resolution after Smoking Cessation. Wolters PJ and Elicker BM. Am J Resp Crit Care Med, 2014, 190: e64.

3. Idiopathic Pulmonary Fibrosis: CT and Risk of Death. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE Jr, Collard HR. Radiology 2014, 273:570-9.

4. Accumulation of BDCA1+ dendritic cells in interstitial fibrotic lung diseases and Th2-high asthma. Greer AM, Matthay MA, Kukreja J, Bhakta NR, Nguyen CP, Wolters PJ, Woodruff PG, Fahy JV, Shin JS. PLoS One 2014, 10: e99084

5. Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt L, Marks JD, Baron JL, and Nishimura SL. Sci Trans Med 2014, 6: 241ra79.

6. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM. Respirology 2014, 19: 740-7.

7. Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis Clinical Research Network. N Engl J Med 2014, 370: 2093-2101.

8. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; the INPULSIS Trial Investigators. N Engl J Med 2014, 370: 2071-2082.

9. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; the ASCEND Study Group. N Engl J Med 2014, 370: 2083-2092.

10. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW. Am J Respir Crit Care Med 2014, 189: 825-31.

11. Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. Jaffar J, Unger S, Corte T, Keller M, Wolters P, Richeldi L, Cerri S, Prêle C, Hansbro P, Argraves W, Oliver R, Oliver B, Black J, and Burgess J. Chest 2014, 146:1055-63.

12. Endogenously expressed IL13Rα2 attenuates IL13-mediated responses but does not activate signaling in human lung fibroblasts. Chandriani S, DePianto DJ, N’Diaye EN, Abbas AR, Jackman J, Bevers J III, Ramirez-Carrozzi V, Pappu R, Kauder SE, Toy K, Ha C, Modrusan Z, Wu LC, Collard HR, Wolters PJ, Egen JG, and Arron JR. J Immunol 2014, 193:111-9.

13. Short telomere length is associated with reduced survival in idiopathic pulmonary fibrosis. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Jones KD, Elicker BM, Kaza V, Girod CE, Ma SF, Vij R, Collard HR, Wolters PJ, and Garcia CK. Lancet Resp Med 2014, 2: 557-65.

14. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. DePianto DJ, Chandriani S, Abbas AR, Jia G, N’Diaye EN, Caplazi P, Kauder SE, Biswas S, Karnik SK, Ha C, Modrusan Z, Matthay MA, Kukreja J, Collard HR, Egen JG, Wolters PJ, and Arron JR. Thorax 2014 (In press).

15. Predicting survival across chronic interstitial lung disease: The ILD-GAP model. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE Jr, and Collard HR. Chest 2014, 145: 723-8.

16. Serum IgE clearance is facilitated by human FcεRI internalization. Greer AM, Wu N, Putnam AL, Woodruff PG, Wolters P, Kinet JP, Shin JS. J Clin Invest 2014, 124: 1187–1198.

17. Rheumatoid Arthritis-associated Interstitial Lung Disease: Radiologic Identification of Usual Interstitial Pneumonia Pattern. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, Lee JS. Radiology 2014, 270: 583-8.

18. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: A prospective cohort study. Ryerson CJ, Cayou C, Topp F, Hilling L, Camp PG, Wilcox PG, Khalil N, Collard HR, Garvey C. Respir Med 2014, 108: 203-10.

19. 6-Minute Walk Test Distance is an Independent Predictor of Mortality in Patients with Idiopathic Pulmonary Fibrosis. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE, Jr. Eur Respir J 2014, 43: 1421-9.

20. Lung Transplantation for Hypersensitivity Pneumonitis. Kern RM, Singer JP, Koth L, Mooney J, Golden J, Hays S, Greenland J, Wolters PJ, Ghio E, Jones K, Leard L, Kukreja J, and Blanc PD. Chest (in press).

21. Overexpression of Id2 Attenuates Pulmonary Fibrosis Through Regulation of c-Abl and Twist. Yang J, Velikoff M, Agarwal M, Disayabutr S, Wolters PJ, and Kim KK. Am J Path (in press).

21. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Costabel U1, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, Du Bois RM. Sarcoidosis Vasc Diffuse Lung Dis. 2014, 31:198-205.

22. Smoking related idiopathic interstitial pneumonia. Flaherty KR, Fell C, Aubry M-C, Brown KK, Colby TV, Costabel C, Franks TJ, Gross BH, Hansell DM, Kazerooni EA, Kim DS, King TE Jr, Kitachi M, Lynch D, Myers J, Nagai S, Nicholson A, Poletti V, Raghu G, Selman M, Toews G, Travis WD, Wells A, Vassallo R, Martinez FJ. Eur Respir J 2014; 44: 594–602.

23. Analysis of Lung Function and Survival in RECAP: An Open-label Extension Study of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Costabel U, Albera C, Bradford WZ, Hormel P, King TE, Jr., Noble PW, Sahn SA, Valeyre D, du Bois RM. Sarcoidosis Vasculitis And Diffuse Lung Disease 2014; 31; 198-205.

24. Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ, and for the IPFnet Investigators. Chest. 2014; 146:1256-1262.

25. Targeting IL-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID IPF model. Murray L, Zhang H, Oak S, Coelho AL, Herath A, Flaherty, K, Lee J, Bell M, Knight D, Martinez F, Selman, M, Herzog E, and Hogaboam C. Am J of Respir Cell and Molecular Biology. 2014, 50:985-94.

2013

1. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Su R, Nguyen ML, Agarwal MR, Kirby C, Nguyen CP, Ramstein J, Darnell EP, Gomez AD, Ho M, Woodruff PG, Koth LL. Respir Res. 2013, 14: 121.

2. BPIFB1 is a Lung-Specific Autoantigen Associated with Interstitial Lung Disease. Shum AK, Alimohammadi M, Tan CL, Cheng MH, Metzger TC, Law CS, Lwin W, Perheentupa J, Carel JC, Husebye ES, De Luca F, Janson C, Sargur R, Dubois N, Kajosaari M, Wolters PJ, Chapman HA, Kämpe O, and Anderson MS. Sci Trans Med 2013, 5 (206) 1-10.

3. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, for the IPFnet Investigators. Lancet Resp Med 2013, 1: 369-376.

4. Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis. Snyder-Cappione JE, Nixon DF, Chi JC, Nguyen ML, Kirby CK, Milush JM, Koth LL. Eur J Immunol. 2013, 43: 2194-2205.

5. Prevalence and Prognosis of Unclassifiable Interstitial Lung Disease. Ryerson CJ, Urbania TH, Richeldi L, Mooney J, Lee JS, Kones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, and Collard HR. Eur Respir J 2013, 42: 750-7.

6. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Lee JS, Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE Jr, Collard HR. Respir Med. 2013, 107: 249-55

7. Genome-wide Association Study Identifies Multiple Susceptibility Loci for Pulmonary Fibrosis. Fingerlin TE, Murphy E, Zhang W, Peljito AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR, Wolters PJ, Bradford WZ, Kossen K, Seiwart SD, du Bios RM, Garcia CK, Devine MS, Gudmundsson G, Isaksson HJ, Kaminski N, Zhang Y, Gibson KF, Lancaster LH, Cogan JD, Mason WR, Maher TM, Molyneaux PL, Wells AU, Moffatt MF, Selman M, Pardo A, Kim DS, Crapo JD, Make BJ, Regan EA, Walek DS, Daniel JJ, Kamatani Y, Zelenika D, Smith K, McKean D, Pedersen BS, Talbert J, Kidd RN, Markin CR, Beckman KB, Lathrop M, Schwarz M, and Schwartz DA. Nature Genetics 2013, 45: 613-20

8. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators. Respir Res. 2013, 13: 73.

9. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, Costabel U, Richeldi L, de Andrade J, Khalil N, Morrison LD, Lederer DJ, Shao L, Li X, Pedersen PS, Montgomery AB, Chien JW, O'Riordan TG; ARTEMIS-IPF Investigators. Ann Intern Med. 2013, 158: 641-9.

10. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen ML, Woodruff PG, Jones KD, Collard HR, King TE, Koth LL. Chest. 2013, 144: 586-92.

11. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Chest. 2013, 144: 234-40.

12. Sildenafil Preserves Exercise Capacity in IPF Patients with Right Ventricular Dysfunction. Han MK, Bach DS, Hagan P, Yow E, Flaherty K, Toews GB, Edwards RH, Anstrom KJ, Martinez FJ; for the IPFnet Investigators. Chest. 2013, 143: 1699-708. (King TE Jr: IPFnet PI)

13. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS; IPFnet Investigators. Respir Med. 2014; 108:181-8. PMID:24388667

2012

1. Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Cha SI, Ryerson CJ, Lee JS, Kukreja J, Barry SS, Jones KD, Elicker BM, Kim DS, Papa FR, Collard HR, Wolters PJ. Respir Res. 2012, 13: 105.

2. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. N Engl J Med. 2012, 366: 1968-77.

3. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR. Ann Intern Med. 2012, 156: 684-91.

4. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Am J Respir Crit Care Med. 2012, 185: 1044-8.

5. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley BM, Elicker B, Jones KD, King TE Jr, Ryu JH, Collard HR. Thorax. 2012, 67: 407-11.

6. Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis. Cha SI, Chang CS, Kim EK, Lee JW, Matthay MA, Golden JA, Elicker BM, Jones K, Collard HR, Wolters PJ. Histopathology. 2012, 61: 98-106.

7. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr, Kim DS, Collard HR. Eur Respir J. 2012, 39: 352-8.

8. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Ryerson CJ, Arean PA, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Respirology. 2012, 17: 525-32.

2011

1. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE Jr, Collard HR. Am J Respir Crit Care Med. 2011, 184: 1390-4.

2. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG. Am J Respir Crit Care Med. 2011, 184: 1153-63.

3. Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit beta8 through altering chromatin architecture. Markovics JA, Araya J, Cambier S, Somanath S, Gline S, Jablons D, Hill A, Wolters PJ, Nishimura SL. J Biol Chem. 2011, 286: 36864-74.

4. Cough predicts prognosis in idiopathic pulmonary fibrosis. Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Respirology. 2011, 16: 969-75.

5. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. J Clin Invest. 2011, 121: 2863-75.

6. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Wootton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H, Lancaster LH, Wolters PJ, DeRisi J, Ganem D, Collard HR. Am J Respir Crit Care Med. 2011, 183: 1698-702.

7. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Lancet. 2011, 377: 1760-9.

8. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR. Chest. 2011, 139: 609-16.

9. Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis. Marmai C, Sutherland RE, Kim KK, Dolganov GM, Fang X, Kim SS, Jiang S, Golden JA, Hoopes CW, Matthay MA, Chapman HA, Wolters PJ. Am J Physiol Lung Cell Mol Physiol. 2011, 301: L71-8.

10. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J. Am J Respir Crit Care Med. 2011, 184: 92-9.

2010

1. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. N Engl J Med. 2010, 363: 620-8.

2. Transcription of the transforming growth factor beta activating integrin beta8 subunit is regulated by SP3, AP-1, and the p38 pathway. Markovics JA, Araya J, Cambier S, Jablons D, Hill A, Wolters PJ, Nishimura SL. J Biol Chem. 2010, 285: 24695-706.

3. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE Jr, Matthay MA, Kim DS. Am J Physiol Lung Cell Mol Physiol. 2010, 299: L3-7.

4. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, Lee JS, King TE Jr, Collard HR. Eur Respir J. 2010, 35:1322-8.

5. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Kinder BW, Shariat C, Collard HR, Koth LL, Wolters PJ, Golden JA, Panos RJ, King TE Jr. Lung. 2010, 188:143-9.

2009

1. Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophages. Atabai K, Jame S, Azhar N, Kuo A, Lam M, McKleroy W, Dehart G, Rahman S, Xia DD, Melton AC, Wolters P, Emson CL, Turner SM, Werb Z, Sheppard D. J Clin Invest. 2009, 119: 3713-22

2. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, du Bois RM; INSPIRE Study Group. Lancet. 2009, 374: 222-8.

3. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Ferreira A, Garvey C, Connors GL, Hilling L, Rigler J, Farrell S, Cayou C, Shariat C, Collard HR. Chest. 2009, 135: 442-7.

4. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA, Chapman HA. J Clin Invest. 2009, 119: 213-24.

2008

1. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, Golden JA. Respir Med. 2008, 102: 150-5.

2. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. Am J Respir Crit Care Med. 2008, 177: 75-81.